Transcriptomic signatures induced by the Ebola virus vaccine rVSVΔG-ZEBOV-GP in adult cohorts in Europe, Africa, and North America: a molecular biomarker study

Garbutt, 2004, Properties of replication-competent vesicular stomatitis virus vectors expressing glycoproteins of filoviruses and arenaviruses, J Virol, 78, 5458, 10.1128/JVI.78.10.5458-5465.2004 Geisbert, 2009, Single-injection vaccine protects nonhuman primates against infection with Marburg virus and three species of Ebola virus, J Virol, 83, 7296, 10.1128/JVI.00561-09 Wong, 2014, Immunization with vesicular stomatitis virus vaccine expressing the Ebola glycoprotein provides sustained long-term protection in rodents, Vaccine, 32, 5722, 10.1016/j.vaccine.2014.08.028 Jones, 2007, Assessment of a vesicular stomatitis virus-based vaccine by use of the mouse model of Ebola virus hemorrhagic fever, J Infect Dis, 196, S404, 10.1086/520591 Marzi, 2019, Single low-dose VSV-EBOV vaccination protects cynomolgus macaques from lethal Ebola challenge, EBioMedicine, 49, 223, 10.1016/j.ebiom.2019.09.055 Suder, 2018, The vesicular stomatitis virus-based Ebola virus vaccine: from concept to clinical trials, Hum Vaccin Immunother, 14, 2107, 10.1080/21645515.2018.1473698 Henao-Restrepo, 2017, Efficacy and effectiveness of an rVSV-vectored vaccine in preventing Ebola virus disease: final results from the Guinea ring vaccination, open-label, cluster-randomised trial (Ebola Ça Suffit!), Lancet, 389, 505, 10.1016/S0140-6736(16)32621-6 Huttner, 2018, Durability of single-dose rVSV-ZEBOV vaccine responses: what do we know?, Expert Rev Vaccines, 17, 1105, 10.1080/14760584.2018.1546582 Huttner, 2017, A dose-dependent plasma signature of the safety and immunogenicity of the rVSV-Ebola vaccine in Europe and Africa, Sci Transl Med, 9, 1, 10.1126/scitranslmed.aaj1701 Ehrhardt, 2019, Polyclonal and convergent antibody response to Ebola virus vaccine rVSV-ZEBOV, Nat Med, 25, 1589, 10.1038/s41591-019-0602-4 Dahlke, 2017, Dose-dependent T-cell dynamics and cytokine cascade following rVSV-ZEBOV immunization, EBioMedicine, 19, 107, 10.1016/j.ebiom.2017.03.045 Joosten, 2012, Identification of biomarkers for tuberculosis disease using a novel dual-color RT-MLPA assay, Genes Immun, 13, 71, 10.1038/gene.2011.64 Huttner, 2015, The effect of dose on the safety and immunogenicity of the VSV Ebola candidate vaccine: a randomised double-blind, placebo-controlled phase 1/2 trial, Lancet Infect Dis, 15, 1156, 10.1016/S1473-3099(15)00154-1 Agnandji, 2016, Phase 1 trials of rVSV Ebola vaccine in Africa and Europe, N Engl J Med, 374, 1647, 10.1056/NEJMoa1502924 Heppner, 2017, Safety and immunogenicity of the rVSVΔG-ZEBOV-GP Ebola virus vaccine candidate in healthy adults: a phase 1b randomised, multicentre, double-blind, placebo-controlled, dose-response study, Lancet Infect Dis, 17, 854, 10.1016/S1473-3099(17)30313-4 Menicucci, 2019, Antiviral innate responses induced by VSV-EBOV vaccination contribute to rapid protection, MBio, 10, 1, 10.1128/mBio.00597-19 Rechtien, 2017, Systems vaccinology identifies an early innate immune signature as a correlate of antibody responses to the Ebola vaccine rVSV-ZEBOV, Cell Rep, 20, 2251, 10.1016/j.celrep.2017.08.023 Pulendran, 2013, Immunity to viruses: learning from successful human vaccines, Immunol Rev, 255, 243, 10.1111/imr.12099 Schoggins, 2011, Interferon-stimulated genes and their antiviral effector functions, Curr Opin Virol, 1, 519, 10.1016/j.coviro.2011.10.008 Huang, 2011, Distinct patterns of IFITM-mediated restriction of filoviruses, SARS coronavirus, and influenza A virus, PLoS Pathog, 7, 10.1371/journal.ppat.1001258 Weidner, 2010, Interferon-induced cell membrane proteins, IFITM3 and tetherin, inhibit vesicular stomatitis virus infection via distinct mechanisms, J Virol, 84, 12646, 10.1128/JVI.01328-10 Pilla-Moffett, 2016, Interferon-inducible GTPases in host resistance, inflammation and disease, J Mol Biol, 428, 3495, 10.1016/j.jmb.2016.04.032 Querec, 2009, Systems biology approach predicts immunogenicity of the yellow fever vaccine in humans, Nat Immunol, 10, 116, 10.1038/ni.1688 Nakaya, 2011, Systems biology of vaccination for seasonal influenza in humans, Nat Immunol, 12, 786, 10.1038/ni.2067 Sokol, 2015, The chemokine system in innate immunity, Cold Spring Harb Perspect Biol, 7, 1, 10.1101/cshperspect.a016303 Pejoski, 2020, Rapid dose-dependent natural killer (NK) cell modulation and cytokine responses following human rVSV-ZEBOV Ebola virus vaccination, NPJ Vaccines, 5, 32, 10.1038/s41541-020-0179-4 Marzi, 2013, Antibodies are necessary for rVSV/ZEBOV-GP-mediated protection against lethal Ebola virus challenge in nonhuman primates, Proc Natl Acad Sci USA, 110, 1893, 10.1073/pnas.1209591110 Warfield, 2018, Role of antibodies in protection against Ebola virus in nonhuman primates immunized with three vaccine platforms, J Infect Dis, 218, S553, 10.1093/infdis/jiy316 Wong, 2012, Immune parameters correlate with protection against Ebola virus infection in rodents and nonhuman primates, Sci Transl Med, 4, 10.1126/scitranslmed.3004582 Huttner, 2018, Determinants of antibody persistence across doses and continents after single-dose rVSV-ZEBOV vaccination for Ebola virus disease: an observational cohort study, Lancet Infect Dis, 18, 738, 10.1016/S1473-3099(18)30165-8 Cao, 2014, Differences in antibody responses between trivalent inactivated influenza vaccine and live attenuated influenza vaccine correlate with the kinetics and magnitude of interferon signaling in children, J Infect Dis, 210, 224, 10.1093/infdis/jiu079 Kazmin, 2017, Systems analysis of protective immune responses to RTS,S malaria vaccination in humans, Proc Natl Acad Sci USA, 114, 2425, 10.1073/pnas.1621489114 Popper, 2018, Early transcriptional responses after dengue vaccination mirror the response to natural infection and predict neutralizing antibody titers, J Infect Dis, 218, 1911, 10.1093/infdis/jiy434 Haralambieva, 2013, Genome-wide characterization of transcriptional patterns in high and low antibody responders to rubella vaccination, PLoS One, 8, 10.1371/journal.pone.0062149 Le Bon, 2006, Cutting edge: enhancement of antibody responses through direct stimulation of B and T cells by type I IFN, J Immunol, 176, 2074, 10.4049/jimmunol.176.4.2074 Kuroda, 2020, Identification of interferon-stimulated genes that attenuate Ebola virus infection, Nat Commun, 11, 10.1038/s41467-020-16768-7 Weinberger, 2018, Impaired immune response to primary but not to booster vaccination against hepatitis B in older adults, Front Immunol, 9, 10.3389/fimmu.2018.01035 Panozzo, 2019, Arthritis and arthralgia as an adverse event following immunization: a systematic literature review, Vaccine, 37, 372, 10.1016/j.vaccine.2018.06.067 Lathrop, 2002, Adverse event reports following vaccination for Lyme disease: December 1998–July 2000, Vaccine, 20, 1603, 10.1016/S0264-410X(01)00500-X Pope, 2013, Possible roles of IL-12-family cytokines in rheumatoid arthritis, Nat Rev Rheumatol, 9, 252, 10.1038/nrrheum.2012.170 Zhang, 2005, Tissue trafficking patterns of effector memory CD4+ T cells in rheumatoid arthritis, Arthritis Rheum, 52, 3839, 10.1002/art.21482 Nam, 2011, Sequential alterations in catabolic and anabolic gene expression parallel pathological changes during progression of monoiodoacetate-induced arthritis, PLoS One, 6, 10.1371/journal.pone.0024320 van Hamburg, 2009, GATA-3 protects against severe joint inflammation and bone erosion and reduces differentiation of Th17 cells during experimental arthritis, Arthritis Rheum, 60, 750, 10.1002/art.24329